Medicago's H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a s...(ed good yields. Vaccine makers curre...)

Vaccine makers currently developing vaccine candidates for the pandemic swine flu using egg-based and cell culture technologies have advised the WHO that the influenza seed strain used to produce their new vaccine is not growing well and therefore giving poor antigen yields. The yield is approximately 25-50% of that vaccine makers typically get for seasonal flu vaccine production. The WHO recently made a new set of seed strains using new viral isolates, such as the California/07, in hopes of increasing the vaccine yield. Medicago's vaccine is produced using its VLP technology that does not require a virus and therefore does not rely on the ability of a viral strain to grow.

About Medicago

Medicago is committed to provide highly effective and affordable vaccines based on proprietary Virus-Like Particle (VLP) and manufacturing technologies. Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants. This technology has potential to offer advantages of speed and cost over competitive technologies. It could deliver a vaccine for testing in about a month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market. Additional information about Medicago is available at www.medicago.com.

Forward Looking Statements

This press release contains forward-looking statements which reflect Medicago's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. Medicago disclaims any ob
'/>"/>